NEW YORK (360Dx) – Cancer detection firm Oncimmune today announced the first distribution deals for its autoantibody-based lung cancer test.

Under the terms of the deals, Israel-based Best Medical Opinion and South Korea-based Dow Biomedica/Biodiscovery will distribute Oncimmune's EarlyCDTLung cancer test in those countries. The agreements allow for the sale of the test as a central laboratory test while Oncimmune finishes the CE marking of a kit form of EarlyCDTLung.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.